A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab‐Treated non‐small Cell Lung Cancer Patients

To assess circulating biomarkers as predictors of antitumor response to atezolizumab (anti‐programmed death‐ligand 1 (PD‐L1), Tecentriq) serum pharmacokinetic (PK) and 95 plasma biomarkers were analyzed in 88 patients with relapsed/refractory non‐small cell lung cancer (NSCLC) receiving atezolizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Netterberg, Ida, Li, Chi‐Chung, Molinero, Luciana, Budha, Nageshwar, Sukumaran, Siddharth, Stroh, Mark, Jonsson, E. Niclas, Friberg, Lena E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704358/
https://www.ncbi.nlm.nih.gov/pubmed/30058723
http://dx.doi.org/10.1002/cpt.1198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704358/
https://www.ncbi.nlm.nih.gov/pubmed/30058723
http://dx.doi.org/10.1002/cpt.1198

Ejemplares similares